CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma
A Study of CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma
Trial Details
- NCT ID
- NCT04661020
- Phase
- PHASE2
- Sponsor
- Zhejiang University
- Status
- RECRUITING
- Cancer Type
- Lymphoma
- Interventions
- Locations (sample)
- Hangzhou, Zhejiang, China|30.29365,120.16142
Key Eligibility Criteria
- Age no less than 18, no gender limit;
- Newly diagnosed high-risk Large B-cell Lymphoma, which was defined by the following criteria: (1) DLBCL not otherwise specified with an IPI score ≥…
- Confirmed CD19 and CD20 postive expressions in lymphoma cells
- ECOG score 0-2;
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lymphoma Trials on Trialify →